Introduction {#s1}
============

Radiotherapy (RT) reduces recurrences and improves cancer-specific survival for patients with breast cancer ([@B1]--[@B3]). However, RT is associated with secondary exposure of the heart and other vital organs to "collateral" radiation injury. A well-cited investigation revealed that the risk of major coronary events increases linearly by 7.4% for every 1 Gy increase in mean heart dose (MHD) ([@B4]). The long-term risk of cardiac morbidity and mortality after irradiation (RT) for left-sided breast cancer is controversial especially for patients undergoing treatment in the current era ([@B4]--[@B6]). Modern RT techniques have significantly reduced cardiac exposure ([@B7]) but the long-term effects of modern RT on cardiac disease remain unknown.

Deep inspiration breath-hold (DIBH) increases the physical separation between the heart and chest wall and thus reduces cardiac exposure during intact breast or chest wall RT ([@B8], [@B9]). Not all patients, however, benefit equally from DIBH. Several studies investigated predictors of cardiac benefit from DIBH with several candidate measures such as maximal heart distance, and cardiac contact distance ([@B10]--[@B13]). Developing patient selection algorithms for DIBH is essential to optimize workflow thus eliminating the need for CT simulation and/or treatment plans in both the free-breathing (FB) and DIBH conditions for all patients with left-sided breast cancer especially in the setting of limited resources (machines, time, etc.). In this study, we aimed to evaluate patient-related non-dosimetric predictors of cardiac sparing with the use of DIBH in patients with left-sided breast cancer undergoing irradiation.

Materials and methods {#s2}
=====================

Patient population
------------------

This study was from a single institution and was approved by the institutional review board. Between December 2015 and May 2017, patients with left-sided breast cancer who underwent whole breast or chest wall irradiation after lumpectomy or mastectomy were identified. Data on patient characteristics such as age, body mass index, and smoking status, in addition to medical co-morbidities \[congestive heart failure (CHF), prior chest surgery, prior lung disease, or presence of simultaneous psychiatric conditions\] were collected. Treatment factors such as tumor stage, type of breast cancer surgery (lumpectomy vs. mastectomy with or without axillary dissection), and chemotherapy regimens were recorded. Written consent to access medical records was obtained from all participants on the study.

DIBH technique, treatment planning, and evaluation metrics
----------------------------------------------------------

Per institutional policy, all patients with left-sided breast cancer underwent free-breathing (FB) and DIBH CT simulations and RT planning in the supine position on a breast board with arms raised above the head. DIBH was combined with infrared optical tracking for body surface imaging for accurate and reproducible patient set-up (AlignRT, VisionRT, London, United Kingdom) as previously described ([@B14]). Portal films and cone-beam CT scans were used as needed.

Target volumes and organs at risk (OARs) were contoured as previously described ([@B15]). Heart contours extended superiorly to the bifurcation of the pulmonary artery. Treatment plans for both the FB and DIBH scans were generated using Prowess® Panther 5.10 (Prowess, Chico, CA). Two opposed tangent fields were typically used for radiation delivery to the breast or chest wall with or without the "field-in-field" technique to further improve dose homogeneity as needed. Additional fields were used to treat the supraclavicular, axillary, or internal mammary lymph nodes, when needed. When 3 fields (2 tangents and a supraclavicular field) were needed, a single mono-isocentric technique with half-beam blocks was used.

Volume delineation was done according to RTOG 1304/NSABP-B51 protocol. Maximum acceptable point dose was ≤ 115% and ≥95% PTV received 95% of the prescribed dose of 50 Gy in 25 fractions. Mean heart dose (MHD) and volume of heart receiving 4 Gy (V4) were collected retrospectively using dose-volume histograms from both FB and DIBH plans. These parameters were selected as MHD (even at low doses) has been associated with increased cardiovascular risk and MHD \< 4 Gy is commonly adopted in treatment planning sections of clinical trials ([@B16]). Timing of CT simulation was stratified into the four known seasons (winter, spring, summer, and fall). Field size was defined as the area being treated by radiation in cm^2^. Time surgery-CT was defined as the time in days from mastectomy or lumpectomy to CT simulation.

Statistics
----------

Continuous variables were reported as mean ± standard deviation. Fisher\'s exact test and Chi-square test were used for univariate analysis and the stepwise method was used for multi-variable analysis. Pearson correlation coefficient was used for correlational analysis. *T*-test and analysis of variance (ANOVA) were used for group comparisons as needed. The Statistical Package for Social Sciences (SPSS version 24.0) was used for all statistical analysis. A *p* ≤ 0.05 in two tailed tests was considered statistically significant for all comparisons.

Results {#s3}
=======

Patient characteristics and treatment planning
----------------------------------------------

One-hundred and three patients were included in this study. Mean age was 51.9 ± 11.8 years. Most patients had T1-2 (88.2%) and node positive (64.1%) disease. Majority of patients did not have any relevant simultaneous comorbidities including lung diseases (98.9% without lung disease), congestive heart failure (98.9% without CHF), psychiatric illness (94% without psychiatric conditions), or prior chest surgery (96% without prior chest surgery). All patients had left-sided breast cancer and the majority underwent mastectomy (97%) and axillary dissection (62.7%). Baseline patient characteristics are reported in Table [1](#T1){ref-type="table"}.

###### 

Baseline patient and treatment characteristics.

  **Characteristics**                                                       ***N* (%)**
  ------------------------- ----------------------------------------------- ------------------------------------------
  Age (years)               Mean (± SD)                                     51.87 (± 11.83)
  BMI (kg/m^2^)             Mean (± SD)                                     27.98 (± 5.17)
  Smoking                   Yes (%) No (%)                                  52 (59.8) 35 (40.2)
  Tumor stage               T0 (%) T1 (%) T2 (%) T3 (%) T4 (%)              1 (1) 55 (53.9) 35 (34.3) 10 (9.8) 1 (1)
  Nodal involvement         Yes (%) No (%)                                  66 (64.1) 37 (35.9)
  Lung disease              Yes (%) No (%)                                  1 (1.1) 87 (98.9)
  CHF                       Yes (%) No (%)                                  1 (1.1) 87 (98.9)
  Prior chest surgery       Yes (%) No (%)                                  4 (4) 96 (96)
  Psychiatric disease       Yes (%) No (%)                                  4 (6) 63 (94)
  Surgery type              Lumpectomy (%) Mastectomy (%)                   3 (2.9) 99 (97.1)
  Axillary dissection       YES (%) NO (%)                                  64 (62.7) 38 (37.3)
  Chemo                     Yes (%) No (%)                                  46 (45.1) 56 (54.9)
  Chemo regimen             AC (%) AC/T (%) EC/T (%) FEC/T (%) Others (%)   8 (16.3) 25 (51) 7 (14.3) 4 (8.2) 5 (10)
  Time Surgery-CT (days)    Mean (± SD)                                     108.14 (± 100.49)
  Seasons (CT simulation)   Winter (%)                                      41 (39.8)
                            Spring (%)                                      19 (18.4)
                            Summer (%)                                      27 (26.2)
                            Fall (%)                                        16 (15.5)
  Field size (cm^2^)        Mean (± SD)                                     218.62 (± 39.83)

*CHF, Congestive Heart Failure; AC, Adriamycin/cyclophosphamide; AC/T, Adriamycin, Cyclophosphamide/Taxanes; EC/T, Epirubicin, Cyclophosphamide/Taxanes; FEC/T, Fluorouracil, Epirubicin, Cyclophosphamide/Taxanes; CT, Computed Tomography; SD, standard deviation*.

All patients tolerated DIBH well. Representative treatment plans for a patient in both the FB and DIBH conditions are showed in Figures [1A,B](#F1){ref-type="fig"} showing the benefit with DIBH in physically removing the heart from beam trajectory. Mean heart dose (MHD) was significantly reduced in the DIBH plans (0.74 ± 0.25 Gy vs. 1.72 ± 0.98 Gy; *p* \< 0.0001; Figure [1C](#F1){ref-type="fig"}). V4 was similarly decreased in the DIBH plans (4 ± 4.98 cc vs. 20.79 ± 18.2 cc; *p* \< 0.0001).

![A representative treatment plan for a patient in both the free-breathing **(A)** and deep inspiration breath-hold **(B)** conditions. Box plot showing the mean heart dose (MHD) in free-breathing and deep inspiration breath-hold **(C)**.](fonc-08-00564-g0001){#F1}

Predictors of cardiac sparing
-----------------------------

We analyzed predictors of cardiac sparing with DIBH using univariate analysis of all factors presented in Table [1](#T1){ref-type="table"}. We used the difference in MHD and V4 between FB and DIBH scans as surrogates of cardiac sparing. Larger body mass index (BMI; *p* = 0.004), non-smoking status (*p* = 0.05), and spring/winter timing of CT simulation (*p* = 0.001) were associated with larger MHD difference between FB and DIBH plans (Table [2](#T2){ref-type="table"} and Figures [2A--C](#F2){ref-type="fig"}). A trend to higher MHDD was noted in obese patients when BMI was plotted as categorical variable (Figure [2C](#F2){ref-type="fig"}). Similarly, larger body mass index (BMI; *p* = 0.005), larger field size (*p* = 0.027), having undergone axillary dissection (*p* = 0.04), prior chemotherapy (*p* = 0.05), and spring/winter timing of CT simulation (*p* = 0.009) were associated with larger V4 difference (Table [3](#T3){ref-type="table"}).

###### 

Univariate analysis of different potential predictors of MHDD (mean heart dose difference) between free-breathing and breath-hold scans.

  **Characteristics**                    **rMHDD/MHDD (± SD)**   ***P*-Value**
  ------------------------- ------------ ----------------------- ---------------
                                         **rMHDD**               
  Age (years)               --           −0.091                  0.359
  BMI (kg/m^2^)             --           0.314                   0.004
  Field size (cm^2^)        --           0.182                   0.066
  Time Surgery-CT (days)    --           0.021                   0.837
                                         **MHDD (**± **SD)**     
  Smoking                   No           1.19 ± 0.89             0.05
                            Yes          0.82 ± 0.79             
  Tumor stage               T0           0.53                    0.987
                            T1           0.99 ± 0.95             
                            T2           0.99 ± 0.74             
                            T3           0.94 ± 0.93             
                            T4           0.81                    
  Nodal involvement         No           1.06 ± 0.87             0.224
                            Yes          0.84 ± 0.85             
  Lung disease              No           0.97 ± 0.89             0.599
                            Yes          1.45                    
  CHF                       No           0.98 ± 0.89             0.993
                            Yes          0.98                    
  Prior chest surgery       No           0.98 ± 0.86             0.272
                            Yes          1.47 ± 0.94             
  Psychiatric disease       No           1.04 ± 0.94             0.639
                            Yes          0.81 ± 0.51             
  Surgery type              Lumpectomy   0.41 ± 0.39             0.25
                            Mastectomy   0.99 ± 0.87             
  Axillary dissection       No           0.98 ± 0.87             0.972
                            Yes          0.99 ± 0.87             
  Chemo                     No           0.99 ± 0.91             0.97
                            Yes          0.98 ± 0.83             
  Seasons (CT simulation)   Winter       1.27 ± 0.91             
                            Spring       1.22 ± 0.96             0.001
                            Summer       0.66 ± 0.68             
                            Fall         0.47 ± 0.45             

*MHDD, Mean heart dose difference between free-breathing and breath-hold scans; rMHDD, Correlation with MHDD; CHF, Cardiac heart failure; CT, Computed Tomography; SD, standard deviation*.

![Box plot showing the mean heart dose difference (MHDD) between free-breathing and deep inspiration breath-hold with respect to timing of CT simulation **(A)**. Correlation between MHDD and body mass index (BMI) plotted as linear **(B)** and categorical variable **(C)**.](fonc-08-00564-g0002){#F2}

###### 

Univariate analysis of different potential predictors of heart DV4 (difference in heart volume receiving 4 Gy or more) between free-breathing and breath-hold scans.

  **Characteristics**                     **Heart DV4**    ***P*-Value**     
  ------------------------- ------------- ---------------- ----------------- -------
  Age (years)               Mean (± SD)   53.79 ± 11.82    49.92 ± 11.61     0.097
  BMI (kg/m^2^)             Mean (± SD)   26.40 ± 4.64     29.57 ± 5.25      0.005
  Smoking                   Yes           19 (46.3)        16 (34.8)         0.27
  Tumor stage               T0            1 (2)            0 (0)             0.61
                            T1            30 (58.8)        25 (49)           
                            T2            16 (31.4)        19 (37.3)         
                            T3            4 (7.8)          6 (11.8)          
                            T4            0 (0)            1 (2)             
  Nodal involvement         Yes           19 (36.5)        18 (35.3)         0.89
  Lung disease              Yes           0 (0)            1 (1)             0.46
  CHF                       Yes           1 (2.1)          0 (0)             1
  Prior chest surgery       Yes           2 (4.1)          2 (3.9)           1
  Psychiatric disease       Yes           2 (5.9)          2 (6.1)           1
  Surgery type              Lumpectomy    2 (3.8)          1 (2)             1
                            Mastectomy    50 (96.2)        49 (98)           
  Axillary dissection       Yes           14 (27.5)        24 (47.1)         0.04
  Chemo                     Yes           23 (45.1)        33 (64.7)         0.05
  Time Surgery-CT (days)    Mean (± SD)   91.48 ± 79.60    124.14 ± 115.69   0.108
  Seasons (CT simulation)   Winter        14 (26.9)        27 (52.9)         
                            Spring        8 (15.4)         11 (21.6)         0.009
                            Summer        18 (34.6)        9 (17.6)          
                            Fall          12 (23.1)        4 (7.8)           
  Field size (cm^2^)        Mean (± SD)   210.09 ± 40.60   227.31 ± 37.44    0.027

*Heart DV4, Difference in heart volume having 4Gy or more between free-breathing and breath-hold scans (normalized to initial heart volume); CHF, Cardiac heart failure; BMI, body mass index; CT, Computed Tomography; SD, standard deviation*.

A multi-variate model was performed for the variables which were significant on univariate analysis. Only BMI (*p* = 0.001) and timing of CT simulation (*p* = 0.001) continued to predict larger MHD difference between FB and DIBH plans (Table [4](#T4){ref-type="table"}). Similarly, only BMI (*p* = 0.03) and timing of CT simulation (*p* = 0.003 and *p* = 0.01) continued to predict larger V4 difference (Table [4](#T4){ref-type="table"}).

###### 

Multivariate analysis for the predictors of MHDD (mean heart dose difference) or heart DV4 (difference in heart volume receiving 4 Gy or more).

  **Variables**                                                          **β (95 % CI)**        ***P*-value**
  ---------------------------------------------------------------------- ---------------------- -------------------
  **MHDD**[^a^](#TN1){ref-type="table-fn"}                                                      
  BMI                                                                    0.05 (0.02; 0.09)      0.001
  Season-Summer                                                          −0.76 (−1.19; −0.34)   0.001
  Season-Fall                                                            −0.60 (−0.95; −0.25)   0.001
  **Variables**                                                          **OR (95 % CI)**       ***P*****-value**
  **Heart DV4 (reference:**\<**2.49)**[^b^](#TN2){ref-type="table-fn"}                          
  BMI                                                                    1.13 (1.01--1.27)      0.03
  Season-Summer                                                          0.20 (0.07--0.59)      0.003
  Season-Fall                                                            0.14 (0.03--0.57)      0.01

*Variables included in the model were BMI, field size, smoking (reference: no), season (reference: winter)*.

*Variables included in the model were BMI, field size, axillary dissection, chemo, season (reference: winter)*.

*BMI, body mass index; OR, odds ratio; MHDD, difference in mean heart dose between free-breathing and breath-hold scans; Heart DV4, difference in heart volume receiving 4 Gy or more between free-breathing and breath-hold scans*.

Discussion {#s4}
==========

In this study, we evaluated non-dosimetric predictors of cardiac sparing with the use of deep inspiration breath-hold (DIBH) in patients with left breast cancer undergoing RT, majority of which were to the chest wall after mastectomy. We identified BMI and timing of CT simulation as significant predictors of benefit from DIBH scans in terms of reduction in MHD or V4. These results are mostly applicable to patients after mastectomy given that most of our patients (97%) underwent mastectomy.

Treatment of left breast cancer benefits from respiratory gating using surface motion tracking systems. This study was carried out in a tertiary care center in a middle income country and was motivated by the need to conserve resources used in treating patients requiring complex motion management systems which not only require an initial capital investment in such systems but also in personnel training and may lead to increased treatment times. We have used the system for 10 years and similar to others, we have confirmed that the implementation of DIBH is feasible, efficacious in reducing cardiac exposure and, adds few extra minutes to treatment time ([@B17]).

Intuitively, patients with unfavorable cardiac anatomy where the heart extends into the treatment fields benefit the most from DIBH. Similarly, patients are more likely to benefit from DIBH after mastectomy compared to lumpectomy ([@B18], [@B19]). Recent studies investigated several candidate predictors of cardiac benefit from DIBH with many potential dosimetric measures such as maximal heart distance, cardiac contact distance, and heart V~50%~\>10 cm^3^ (volume \>10 cm^3^ of the heart receiving 50% of the prescribed dose) ([@B10]--[@B13]). While these measures allowed a better understanding of benefit after DIBH and a better selection of patients, our study sought to identify patient-related non-dosimetric factors that may aid the decision to select patients for DIBH even before the breath hold scan is performed.

Several factors were identified in our study but only BMI and timing of CT simulation were statistically significant on multi-variate analysis. Larger BMI was associated with increased MHD difference after DIBH. Previously, the relevance of BMI to benefit after DIBH has been controversial. One study using active breathing control (ABC) DIBH showed that BMI did not correlate with cardiac sparing ([@B20]) in contrary to other studies which showed the opposite ([@B21], [@B22]). In fact, the correlation between BMI and change in MHD corresponds to to 6.06 cGy/kg/m^2^ ([@B22]).It has been proposed by others that heart motion could differ with increased body habitus ([@B22]). Most interestingly, patients who underwent treatment planning in winter/spring reaped more cardiac sparing than those in summer/fall. This is possibly related to the seasonal variations in lung function with a predicted decline in lung function from July to September corresponding to the summer/fall seasons ([@B23]). Alternatively, this could be due to the high humidity in Beirut during summer time.

The current study is limited by its retrospective nature and the relatively low mean heart dose in our cohort in the FB conditions indicating that the majority of patients had favorable cardiac anatomy. This, however, probably reflects a real life breast cancer patient cohort in a tertiary care center in the Middle East. Indeed, DIBH benefit is not limited to patients with unfavorable cardiac anatomy as shown previously ([@B13]). While the question of conserving resources is extremely important in low and middle income countries, it is equally important in high income countries as well. The large number of cases in this study reflecting a representative population of patients with breast cancer increases its significance in all radiotherapy centers. Another limitation of this study is the absence of detailed dosimetric analysis of sub-cardiac structures whose exposure has been linked to deleterious cardiac events such as the left anterior descending artery ([@B24], [@B25]). The absence of specific dose constraints to these structures precluded such detailed analysis. In addition, the clinical relevance of heart V4 needs to be validated in prospective studies. Finally, the correlation between DIBH benefit and CT simulation time is limited to cities around the Mediterranean with seasonal weather like that in Beirut. Radiation oncologists are thus urged to utilize all possible techniques to reduce cardiac dose in patients undergoing RT for left sided breast cancer. Whereas, the long-term consequences of cardiac exposure during left breast/chest wall RT remain controversial at best, RT causes volume-dependent perfusion defects within 2 years of RT with corresponding wall-motion abnormalities ([@B26]). Surface motion tracking is a very powerful tool to this effect but it may not be feasible to apply for all patients in the setting of limited resources due to additional cost, time and labor associated with its implementation. In addition to dosimetric parameters such as maximum heart distance and cardiac contact distance, BMI and timing of treatments can be used to aid in patient selection for DIBH treatment. Further work is needed to eventually be able to create an algorithm which will identify those patients who are ideal candidates for DIBH scans. In conclusion, whenever resources are restrained our data suggests that patients BMI needs to be taken into account when considering DIBH treatment technique.
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